Assessing AI for Detecting Lung Nodules and Cancer: Pre- and Post-Deployment Study
NCT ID: NCT06746324
Last Updated: 2025-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2025-05-15
2026-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
No changes will be made to patients' standard care, and all treatment decisions will be based on the clinical judgment of physicians. The study includes patients over 35 years old who undergo chest X-rays for various medical reasons, excluding those with known lung cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule.
NCT05817110
Trial of Artificial Intelligence for Chest Radiography
NCT06456203
Standalone Observational Study Assessing the Performance of an AI/ML Tech-based SaMD on Chest LDCT Images (REALITY)
NCT06576232
Advancing Lung Cancer Screening: Artificial Intelligence, Multimodal Imaging and Cutting-Edge Technologies for Early Detection and Characterization
NCT06531343
AI Models for Predicting Occult Pleural Dissemination in NSCLC
NCT07065422
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to assess differences in lung nodule detection rates and the percentage of lung cancers diagnosed through the nodule pathway between the two cohorts. Secondary objectives include evaluating whether the AI tool aids in detecting more early-stage lung cancers and identifying reasons for patients dropping out of the nodule clinic pathway.
In the post-deployment cohort, qXR-LN integrates seamlessly with the hospital's existing systems to provide real-time AI findings on radiologists' workstations. Radiologists can accept or reject AI suggestions, ensuring that the final decisions remain under human supervision. Data from both cohorts, including patient demographics, nodule detection rates, cancer diagnoses, and treatment outcomes, will be collected and analyzed.
The study excludes patients under 35 years old and those with known lung cancer at the time of imaging. Ethical considerations include obtaining waivers of consent where applicable and ensuring minimal risk to participants. The findings of this study aim to inform clinical practices and enhance the use of AI tools in lung cancer screening and diagnosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pre-Deployment Cohort
Patients undergoing standard chest X-rays prior to the introduction of the AI-based Computer Aided Detection (CAD) system. This cohort represents the baseline population used for comparison, with no AI intervention applied during their imaging or reporting process.
No interventions assigned to this group
Post-Deployment Cohort
Patients undergoing chest X-rays after the AI-based Computer Aided Detection (CAD) tool has been integrated into the clinical workflow. Although not assigned as an "intervention group" per a traditional trial protocol, these patients receive imaging evaluated by the AI tool, and the impact on diagnostic outcomes will be compared to the pre-deployment cohort.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chest X-ray must be obtained as part of routine care (e.g., ordered for respiratory complaints, screening, or other clinical indications)
* Chest X-ray performed using CR/DR/DX imaging modality
* Examination described as "Chest"
* View: PA or AP
* Patient positioned as Erect or Supine
* Image available in valid DICOM format with proper DICOM prefix values (including "DICM" in the header)
Exclusion Criteria
* Patients with known lung cancer at the time of chest X-ray acquisition
* Lateral views or any imaging modality other than CR/DR/DX
* Imaging or anatomy not specified as Chest (e.g., different body parts or modalities)
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
qXR-LN-UFL-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.